U.S. Hospitality Stock News

NasdaqGS:COIN
NasdaqGS:COINCapital Markets

A Look At Coinbase Global (COIN) Valuation After Regulatory Setbacks And Crypto Market Weakness

Interest in Coinbase Global (COIN) has picked up after a series of regulatory setbacks, crypto market weakness, and cautious analyst views, even as the company rolls out new services to broaden its business. See our latest analysis for Coinbase Global. Recent headlines around regulatory scrutiny, cautious earnings expectations, and a weaker crypto backdrop have gone hand in hand with a 24.0% year to date share price decline. At the same time, the 3 year total shareholder return of about 1.5x...
NYSE:RNG
NYSE:RNGSoftware

RingCentral TELUS AI Partnership Puts Carrier Distribution In Focus

RingCentral (NYSE:RNG) and TELUS announced an expanded partnership to add advanced AI powered features to the TELUS Business Connect platform. The new capabilities focus on automation, customer engagement, and employee productivity within the cloud communications suite. The update highlights RingCentral’s use of proprietary AI solutions in a carrier partner offering that serves business customers across Canada. For context, RingCentral operates in the cloud communications and collaboration...
NYSE:PARR
NYSE:PARROil and Gas

Is It Too Late To Consider Par Pacific Holdings (PARR) After A 121% One-Year Rally?

If you are wondering whether Par Pacific Holdings' share price still reflects good value or if too much optimism is already priced in, this article walks through the key numbers that matter for you. The stock recently closed at US$39.25, with returns of 11.9% over the past 7 days, 9.6% over the past 30 days, and 121.1% over the last year, which has put valuation firmly on many investors' radar. Recent news coverage has focused on Par Pacific Holdings as an energy refiner and marketer that...
NYSE:DAVA
NYSE:DAVAIT

A Look At Endava (DAVA) Valuation As Growth Outlook And Client Spending Are Reassessed

Why Endava is back on investors’ radar Endava (DAVA) is drawing fresh attention after recent commentary highlighted slower revenue growth, cautious enterprise customer spending, conservative guidance, and a more measured view of its longer term growth prospects. See our latest analysis for Endava. That cautious tone has been reflected in Endava’s recent trading, with a 1 day share price return of 10.24% decline and a 90 day share price return of 36.9% decline. The 1 year total shareholder...
NYSE:CCL
NYSE:CCLHospitality

Carnival Corporation (CCL) Valuation Check After Record Revenue, Higher Profits And Dividend Resumption

Renewed attention on Carnival Corporation & (CCL) follows its record 2025 revenue, higher profits, and management’s decision to resume dividends while continuing to reduce pandemic era debt obligations. See our latest analysis for Carnival Corporation &. The share price has eased 1.6% over the last day, but that comes after an 11.3% 7-day gain and an 18.7% 90-day share price return. The 3-year total shareholder return of 162% and 5-year total shareholder return of 52% point to momentum that...
NYSE:TMO
NYSE:TMOLife Sciences

Is Thermo Fisher Scientific (TMO) Pricing Look Reasonable After Recent Share Price Weakness

If you are wondering whether Thermo Fisher Scientific's current share price reflects its long term potential, you are not alone. This article will help you frame what the recent moves might mean for value focused investors. The stock last closed at US$570.09, with returns of an 8.6% decline over the past 7 days, a 3.8% decline over the past month, and a 3.8% decline year to date, while the 1 year return is a 1.5% decline and the 5 year return stands at 18.1%. Recent share price moves have...
NYSE:NVT
NYSE:NVTElectrical

Is nVent Electric (NVT) Using Investor Day to Recast Its Long‑Term Growth Playbook?

nVent Electric plc recently announced plans to host its 2026 Investor Day on February 24, featuring senior leadership presentations on updated medium-term financial objectives and the next phase of its growth strategy, with live and on-demand webcasts available via its Investor Relations website. This event underscores management’s effort to provide greater transparency around the company’s growth priorities, offering investors a closer look at how its electrical connection and protection...
NYSE:MCD
NYSE:MCDHospitality

McDonald's Caviar McNuggets And New Leaders Shape Brand And Investor Focus

McDonald's launched limited-edition McNugget Caviar kits in partnership with Paramount Caviar, pairing Chicken McNuggets with premium caviar and specialty sauces. The company also announced leadership changes, including Luis Quintiliano becoming U.S. National Field president and several senior finance rotations. These updates arrive as McDonald's, ticker NYSE:MCD, continues to draw attention from both consumers and investors. For investors, the timing of these moves comes with McDonald's...
NYSE:HCA
NYSE:HCAHealthcare

The Bull Case For HCA Healthcare (HCA) Could Change Following AI-Driven Efficiency Push And Major Buyback Program

In late January 2026, HCA Healthcare reported Q4 and full-year 2025 results showing higher sales, earnings, and diluted EPS, while also issuing 2026 guidance, raising its quarterly dividend to US$0.78 per share, and authorizing a new US$10.00 billion share repurchase program. Management underscored that these financial results were supported by nineteenth consecutive quarter volume growth and expanding AI-driven efficiency initiatives across HCA’s hospital network. Next, we’ll examine how...
NasdaqGS:MRCY
NasdaqGS:MRCYAerospace & Defense

The Bull Case For Mercury Systems (MRCY) Could Change Following Record Backlog And Narrowing Losses – Learn Why

Mercury Systems recently reported fiscal second-quarter 2026 results, with sales rising to US$232.87 million and net loss narrowing to US$15.1 million compared with the prior year period. Beyond the headline beat on revenue and adjusted earnings, the company’s record backlog approaching US$1.50 billion underscores strong order inflows and program momentum across areas like space and advanced air mobility. We’ll now explore how these better-than-expected results and record backlog shape...
NasdaqGM:BLBD
NasdaqGM:BLBDMachinery

Assessing Blue Bird (BLBD) Valuation After Strong Recent Share Price Momentum

Why Blue Bird Stock Is On Investors’ Radar Blue Bird (BLBD) has drawn fresh attention after a period of strong share performance, with the stock up 12.1% over the past month and 2.1% over the past 3 months. See our latest analysis for Blue Bird. The recent 12.2% year to date share price return, alongside a 45% total shareholder return over the past year and very large 3 year gains, points to momentum that reflects changing expectations around Blue Bird’s growth prospects and risks at a share...
NasdaqGS:MDGL
NasdaqGS:MDGLBiotechs

Does Madrigal Pharmaceuticals (MDGL) Offer Value After Recent Share Price Weakness

If you are wondering whether Madrigal Pharmaceuticals' current share price reflects its true worth, this article will walk through what the numbers are saying about value. The stock last closed at US$482.45, with a 7 day return of a 3.6% decline, a 30 day return of an 18.8% decline and a year to date return of an 18.8% decline, while the 1 year return sits at 49.4%, the 3 year return at 75.4% and the 5 year return at 285.3%. Recent attention on Madrigal Pharmaceuticals has centered on...
NYSE:MOG.A
NYSE:MOG.AAerospace & Defense

Why Moog (MOG.A) Is Up 12.6% After Boosting Outlook, Dividend And Completing Buybacks

Moog Inc. reported strong first-quarter 2026 results on January 30, 2026, with sales rising to US$1,100.35 million and net income increasing to US$78.85 million, alongside higher earnings per share, a raised full-year sales outlook to US$4.3 billion, and a quarterly dividend lifted to US$0.30 per share. These moves, combined with the completion of a multi-year share repurchase program and ongoing confidence in aerospace and defense demand, signal management’s willingness to return cash to...
NasdaqGS:COGT
NasdaqGS:COGTBiotechs

Assessing Cogent Biosciences (COGT) Valuation After FDA Breakthrough Therapy And Real Time Oncology Review News

Cogent Biosciences (COGT) recently reported two closely linked FDA milestones for its lead cancer therapy, and those regulatory updates are now central to how many investors are thinking about the stock. See our latest analysis for Cogent Biosciences. The FDA’s Breakthrough Therapy Designation and Real-Time Oncology Review decision arrived after a period of very strong market interest, with the share price at $37.28 and a 90 day share price return of 158.53%. The 1 year total shareholder...
NasdaqGM:ENPH
NasdaqGM:ENPHSemiconductor

Enphase Energy Expands Home Energy Reach With Bidirectional EV Charging Pilots

Enphase Energy (NasdaqGM:ENPH) is progressing its DC based IQ Bidirectional EV Charging Platform, with global pilot demonstrations and validation in the US and key European markets. The platform is being developed to support EV charging, home backup power and potential future grid services. The company is targeting volume production of the IQ Bidirectional EV Charging Platform beginning in late 2026. For you as an investor, this move extends Enphase Energy beyond its core residential solar...
NasdaqGS:INCY
NasdaqGS:INCYBiotechs

Is Incyte (INCY) Offering Value After A 36% One Year Share Price Gain

If you are wondering whether Incyte's current share price lines up with its underlying worth, you are not alone. This article is designed to help you connect the dots between price and value. Incyte's share price recently closed at US$100.92, with returns of a 2.5% decline over 7 days, a 0.5% decline over 30 days, a 0.5% decline year to date, and a 36.2% gain over the past year, which hints at shifting expectations about the stock. Recent headlines around Incyte have focused on the company's...
NYSE:GRMN
NYSE:GRMNConsumer Durables

Garmin’s New Varia RearVue 820 Deepens Cycling Safety Ecosystem

Garmin (NYSE:GRMN) has introduced the Varia RearVue 820 radar tail light for cyclists. The product adds vehicle tracking, dynamic threat level alerts, and customizable lighting modes focused on rider safety. The launch expands Garmin's cycling safety technology lineup within its fitness and outdoor segment. For investors watching Garmin, the Varia RearVue 820 sits squarely in the company’s core fitness and outdoor business, where connected devices and safety features are an important part...
NYSE:BY
NYSE:BYBanks

Earnings Beat, Higher Dividend and Buybacks Might Change The Case For Investing In Byline Bancorp (BY)

Byline Bancorp, Inc. reported past fourth-quarter 2025 results with net interest income of US$101.26 million and net income of US$34.52 million, alongside a 20% increase in its quarterly dividend to US$0.12 per share. The company also completed a share repurchase program and reduced net loan and lease charge-offs, highlighting capital return to shareholders while maintaining asset quality. Next, we'll examine how the earnings beat and dividend increase affect Byline Bancorp's investment...
NYSE:EDU
NYSE:EDUConsumer Services

New Oriental Education & Technology Group (EDU) Is Up 13.5% After Upbeat Q2 Results, Guidance And Buyback – Has The Bull Case Changed?

New Oriental Education & Technology Group recently reported past second-quarter fiscal 2026 results showing higher sales and net income, issued revenue guidance projecting further year-over-year growth for the third quarter and full year, and completed a US$86.3 million repurchase of 1,600,000 shares representing 1.01% of its share base. The combination of improving profitability, management’s outlook for continued revenue expansion, and capital returned through completed buybacks highlights...
NasdaqGS:ACLX
NasdaqGS:ACLXBiotechs

Assessing Arcellx (ACLX) Valuation After New D Domain CAR T Data Draws Fresh Investor Attention

Why Arcellx Stock Is Back in Focus After New CAR T Data Arcellx (ACLX) is back on investors’ radar after late breaking data on its D Domain binder in anitocabtagene autoleucel was accepted for presentation at the 2026 Tandem Meetings. The abstract centers on preclinical comparisons of different BCMA targeted CAR T constructs, highlighting how binder design may affect specificity, safety signals, and cytokine release in multiple myeloma treatment. For investors, this development relates less...
NYSE:SKY
NYSE:SKYConsumer Durables

Is Champion Homes (SKY) Starting To Look Interesting After Recent Share Price Weakness

If you are wondering whether Champion Homes is starting to look like value after a weak share price patch, this article will walk through what the current price might be implying about the business. The stock last closed at US$76.03, with returns of an 11.8% decline over 7 days, a 10.5% decline over 30 days, a 10.5% decline year to date, but a 10.5% gain over 3 years and an 81.1% gain over 5 years. This mix of short term weakness and longer term gains can leave investors questioning whether...
NYSE:UNH
NYSE:UNHHealthcare

Regulatory Pressures Test UnitedHealth Group Earnings Outlook And Valuation Gap

UnitedHealth Group (NYSE:UNH) is under Department of Justice investigation over its Medicare billing practices. Regulators are scrutinizing how the company handles Medicare Advantage payments and related coding activity. Proposed Medicare Advantage rates for 2027 include a near-zero increase, pressuring economics across the program. New Department of Labor rules call for extensive transparency from Pharmacy Benefit Managers that work with employers. For a company as large and diversified as...
NasdaqGS:SRRK
NasdaqGS:SRRKBiotechs

Scholar Rock Insider Sales Coincide With Key Apitegromab Launch Decisions

Scholar Rock Holding's Chief Scientific Officer has executed multiple insider share sales under a pre-arranged 10b5-1 trading plan. The transactions come as the company readies apitegromab, its muscle-targeted treatment, for potential launch in the U.S. and Europe pending regulatory approvals. The timing links leadership share activity with a period of important commercialization preparations for the company. Scholar Rock Holding (NasdaqGS:SRRK) is drawing fresh attention as insider trading...